Swiss National Bank’s Stemline Therapeutics, Inc. STML Stock Holding History

Swiss National Bank’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-87,400	Closed	-$423K	–	2572
2020 Q1	$423K	Buy	87,400 +3,600	+4%	+$23.3K	﹤0.01%	2245
2019 Q4	$891K	Buy	83,800 +1,200	+1%	+$11.9K	﹤0.01%	2204
2019 Q3	$860K	Buy	82,600 +18,200	+28%	+$238K	﹤0.01%	2133
2019 Q2	$987K	Sell	64,400 -6,000	-9%	-$86.8K	﹤0.01%	2118
2019 Q1	$905K	Buy	70,400 +21,100	+43%	+$239K	﹤0.01%	2118
2018 Q4	$468K	Buy	+49,300	New	+$639K	﹤0.01%	2376
2014 Q2	–	Sell	-7,700	Closed	-$157K	–	2562
2014 Q1	$157K	Buy	7,700 +2,400	+45%	+$58.2K	﹤0.01%	2448
2013 Q4	$104K	Buy	+5,300	New	+$141K	﹤0.01%	2473

Swiss National Bank's STML Position: Q2 2020 in Review

Swiss National Bank sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 87,400 shares — an estimated $423K sold.

Swiss National Bank first reported a position in STML in Q4 2013 and held it in 8 quarters. The position peaked at $987K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Swiss National Bank reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Swiss National Bank sold 87,400 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $423K.
Swiss National Bank first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 8 quarters.
Swiss National Bank's Stemline Therapeutics, Inc. position peaked at $987K in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.